Clin Assess
For more than 22 years, Clin Assess is a CRO that pursue its work with great passion. They work on commercial studies including those with a high patient number.
Customers appreciate their medical background, their expertise, and the precision in which they achieve their goals and realise all phases of the clinical trial with pinpoint accuracy.
They rely on clear project communication with interactive feedback, provide individual support for their customers and accompany them step by step from the beginning and through all stages of the project.
Their employees are specialists from the pharmaceutical industry, contract research and the clinical sector. They have special expertise in the fields of oncology, cardiovascular diseases, infectious diseases, immunotherapy, personalised medicine and diseases of the central nervous system.
Learn more: www.clinassess.de
A LEADING POSITION AND
AN INTERNATIONAL DEPLOYMENT
64 +
countries
involved
20 000 +
investigational
Centres
3 million +
patients
in database
50 000 +
users
worlwide
LATEST NEWSOUR NEWS >
June 27, 2024
25 September 2024 from 4:00PM to 5:30PM (CEST) Webinar Overview It has been demonstrated that using standards from the start of clinical research studies (i.e. protocol and CRF development) can save significant time and resources and results in higher quality research. Unfortunately, it is not always clear how to select the appropriate standards for the […]
June 27, 2024
Applied Clinical Trials Online ACT: How can data management challenges be addressed? Specifically, is there any opportunity to address them with artificial intelligence (AI)? Lacroix: There is a lot of opportunity across the life cycle to assist with this and it’s interesting because historically it was always: we want to throw people at some of […]
June 27, 2024
Fiercebiotech Experts recommend that CGT manufacturers proactively design a comprehensive market access strategy early in clinical development and commercial planning timelines, ideally more than three years prior to launch. This strategy should focus on addressing the nuanced market access challenges for such treatments, including but not limited to, distribution network design, tailored commercial site engagement, […]